Open AccessHealth Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland
Author(s) -
Ulrich Heininger,
Matthew Pillsbury,
Salome Samant,
Florian Lienert,
Patrik Guggisberg,
Ray Gani,
Elliott O'Brien,
Manjiri Pawaskar
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003136
Subject(s) - vaccination , virology , medicine , environmental health
Varicella, caused by the varicella-zoster virus, is a highly contagious infectious disease with substantial health and economic burden to society. Universal varicella vaccination (UVV) is not yet recommended by the Swiss National Immunization Program, which instead recommends catch-up immunization for children, adolescents and adults 11-40 years of age who have no reliable history of varicella or are varicella-zoster virus-IgG seronegative. The objective of this study was to perform an assessment of health impact and cost-effectiveness comparing UVV with current practice and recommendations in Switzerland.